Get the Stockscreener App
54.90
4.77%
-2.75
Pre-market:
56.01
1.11
+2.02%
Protagonist Therapeutics Inc Stock (PTGX) Latest News
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out - MSN
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Acquired by Bank of New York Mellon Corp - Defense World
Protagonist Therapeutics’ SWOT analysis: promising pipeline drives stock outlook - Investing.com
Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why - Yahoo Finance
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $72.00 at BMO Capital Markets - Defense World
Protagonist Therapeutics (NASDAQ:PTGX) Hits New 1-Year High on Analyst Upgrade - Defense World
Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It (NASDAQ:PTGX) - Seeking Alpha
Wedbush Adjusts Protagonist Therapeutics Price Target to $70 From $58, Maintains Outperform Rating - Marketscreener.com
Protagonist Therapeutics Soars as Icotrokinra Drives Breakthroug - GuruFocus.com
Protagonist Therapeutics price target raised to $76 from $60 at Truist - TipRanks
Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success - Yahoo Finance
Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Protagonist Therapeutics price target raised to $72 from $62 at BMO Capital - TipRanks
Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday - Yahoo Finance
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Shares Climb 44% But Its Business Is Yet to Catch Up - Simply Wall St
Protagonist Therapeutics price target raised to $80 from $54 at H.C. Wainwright - TipRanks
Protagonist Therapeutics Gets IBD Stock Rating Upgrade - Investor's Business Daily
10 Firms Buck Market Bloodbath on Monday - Insider Monkey
Protagonist Therapeutics Earns Relative Strength Rating Upgrade - Inkl
Protagonist Therapeutics’ (PTGX) Buy Rating Reaffirmed at HC Wainwright - Defense World
PTGX stock soars to 52-week high, reaching $50.18 By Investing.com - Investing.com Australia
BTIG maintains Buy on Protagonist Therapeutics, target at $73 By Investing.com - Investing.com Canada
Truist raises Protagonist Therapeutics target to $76 - Investing.com
Truist raises Protagonist Therapeutics target to $76 By Investing.com - Investing.com UK
Why Is Protagonist Therapeutics Stock Trading Higher On Monday? - Benzinga
Truist Securities Adjusts Price Target on Protagonist Therapeutics to $76 From $60, Keeps Buy Rating - Marketscreener.com
Protagonist Therapeutics rises as bowel disease drug succeeds mid-stage study - TradingView
Protagonist reports top line results from Phase 2b study of icotrokinra - TipRanks
PTGX stock soars to 52-week high, reaching $50.18 - Investing.com India
Why Protagonist Therapeutics Shares Are Under Pressure - TipRanks
Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis - ACCESS Newswire
BTIG maintains Buy on Protagonist Therapeutics, target at $73 - Investing.com India
JMP reiterates $61 target for Protagonist Therapeutics stock - Investing.com
JMP reiterates $61 target for Protagonist Therapeutics stock By Investing.com - Investing.com Canada
Promising Potential of Protagonist Therapeutics’ Icotrokinra in Psoriasis Treatment: A New Benchmark for Oral Therapies - TipRanks
Protagonist Therapeutics: Buy Rating Backed by Promising Phase 3 Results and Market Potential of Icotrokinra - TipRanks
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives $55.89 Average Price Target from Analysts - Defense World
Protagonist Therapeutics Inc (PTGX) Announces Promising Phase 3 Results for Icotrokinra in Psoriasis Treatment - GuruFocus.com
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Protagonist Therapeutics (NASDAQ:PTGX) Stock - Defense World
Positive Phase III VERIFY results of rusfertide in PV - The Pharma Letter
H.C. Wainwright maintains Buy rating on Protagonist Therapeutics stock By Investing.com - Investing.com Australia
H.C. Wainwright maintains Buy rating on Protagonist Therapeutics stock - Investing.com India
Truist maintains Buy on Protagonist Therapeutics, $60 target By Investing.com - Investing.com Canada
Protagonist Therapeutics (NASDAQ:PTGX) Receives “Buy” Rating from HC Wainwright - Defense World
Protagonist Therapeutics: Buy Rating Affirmed on Rusfertide’s Phase 3 Success and Market Potential - TipRanks
Protagonist Therapeutics: Strong Buy Rating Backed by Promising Phase 3 Results and Robust Financial Outlook - TipRanks
Protagonist Therapeutics: Positive VERIFY Trial Results and Promising Financial Prospects Justify Buy Rating - TipRanks
Protagonist Therapeutics CFO Ali Asif reports stock sale - MSN
Takeda/Protagonist’s Rusfertide Could Be A Main Character In PV After Phase III Data - Citeline News & Insights
Truist maintains Buy on Protagonist Therapeutics, $60 target - Investing.com
Protagonist Therapeutics price target raised to $73 from $67 at BTIG - TipRanks
Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer - AOL
News Flash: 10 Analysts Think Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Earnings Are Under Threat - Yahoo Finance
Protagonist Therapeutics’ Rusfertide: A Promising Blockbuster in the Polycythemia Vera Market with Strong Buy Rating - TipRanks
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera - Business Wire
Allspring Global Investments Holdings LLC Decreases Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
HC Wainwright Brokers Increase Earnings Estimates for PTGX - MarketBeat
JPMorgan maintains Overweight on Protagonist Therapeutics stock - Investing.com
JPMorgan maintains Overweight on Protagonist Therapeutics stock By Investing.com - Investing.com Canada
The Goldman Sachs Group Has Lowered Expectations for Protagonist Therapeutics (NASDAQ:PTGX) Stock Price - MarketBeat
Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event - ACCESS Newswire
Rhumbline Advisers Sells 2,214 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):